Testosterone Cypionate in Adolescents (Ages 12 to 17): Transitioning to Adult Care

Why Transition Planning Matters for Young Patients on Testosterone Cypionate

Transition from pediatric to adult care is one of the highest-risk periods for adolescents on any chronic therapy. For testosterone cypionate specifically, a gap in coverage can interrupt pubertal progression, reduce bone mineral density accrual, and destabilize mood in patients who have already responded to therapy. The Endocrine Society's 2023 Clinical Practice Guideline on hypogonadism states that "continuity of androgen replacement is essential during late adolescence to complete virilization and achieve peak bone mass." [1]

Testosterone cypionate (TC) is a long-acting injectable ester of testosterone with a half-life of approximately 8 days. [2] This means a single missed injection cycle at the transition boundary can produce symptomatic hypogonadism within two weeks.

Who Needs This Transition?

Three groups of adolescents receive testosterone cypionate:

• Adolescents with hypogonadotropic hypogonadism (e.g., Kallmann syndrome, constitutional delay).
• Adolescents with primary hypogonadism (e.g., Klinefelter syndrome, 47,XXY).
• Transgender adolescent males receiving gender-affirming hormone therapy (GAHT).

Each group has slightly different endpoints for transition, but all share the same structural need: a receiving adult provider, a complete medication record, and a laboratory baseline transferred before age 18. [3]

Epidemiology and Scope

Klinefelter syndrome affects approximately 1 in 660 male births, making primary hypogonadism the most common indication for long-term testosterone therapy initiated in adolescence. [4] Hypogonadotropic hypogonadism is less prevalent but carries higher complexity because LH and FSH must be monitored separately from testosterone levels. [5]

Testosterone Cypionate Dosing in Adolescents: Baseline Before Transition

Understanding where a patient is in their dose trajectory shapes the entire handoff plan. Pediatric endocrinologists typically start testosterone cypionate at sub-adult doses and escalate over 18 to 24 months. [6]

Standard Adolescent Dose Escalation Schedule

The Endocrine Society recommends starting testosterone ester therapy at 25 to 50 mg intramuscularly every 4 weeks, increasing every 6 months toward adult doses. [1] A practical schedule looks like this:

• Year 1 (early puberty induction): 50 mg IM every 4 weeks.
• Year 2 (mid-puberty): 75 to 100 mg IM every 4 weeks.
• Year 3+ (late puberty, near-adult dosing): 100 to 150 mg IM every 2 weeks.

By the time most patients approach their 18th birthday, they are already on doses within the adult maintenance range of 100 to 200 mg every 1 to 2 weeks. [2]

Bone Age and Growth Plate Monitoring

Testosterone accelerates epiphyseal closure. Bone age radiographs of the non-dominant hand are obtained every 6 to 12 months during active dose escalation. [1] Premature closure is a real risk if doses are escalated too quickly in patients with open growth plates. A 2017 study in the Journal of Clinical Endocrinology and Metabolism (N=83 adolescent males with hypogonadotropic hypogonadism) found that careful dose titration targeting mid-normal testosterone ranges preserved final adult height within 1.3 SDs of predicted height. [7]

Hematocrit and Cardiovascular Surveillance

Testosterone cypionate raises erythropoiesis. In adolescents, hematocrit should be checked every 6 months during escalation and annually once stable. [1] A hematocrit above 54% warrants dose reduction or an extended injection interval before transition, not after. [6] The adult provider needs to receive a hematocrit trend, not just a single value.

The Formal Transition: What Happens at Age 18

Transition is not a single appointment. Best practice, endorsed by the American Academy of Pediatrics and the Society for Adolescent Health and Medicine, is a structured process beginning at least 12 months before the actual transfer date. [8]

Six-Month Pre-Transfer Checklist

At least six months before the patient turns 18, the pediatric team should:

1. Identify an adult endocrinologist, urologist, or primary care physician willing to accept the patient.
2. Complete a bone density scan (DXA) if one has not been done in the prior 24 months. [9]
3. Obtain a full laboratory panel: total testosterone (trough, drawn just before the next injection), free testosterone, LH, FSH, hematocrit, hemoglobin, lipid panel, liver function tests, and metabolic panel.
4. Compile a written transition summary documenting all doses used, injection intervals, adverse events, and the patient's own treatment goals.
5. Send the transition summary to the receiving provider and confirm receipt.

At the Transfer Appointment

The first adult-care visit should occur within 4 to 8 weeks of the 18th birthday, before the prescription authorization lapses. [8] At that visit, the adult provider should:

• Review the transferred laboratory results and compare to reference ranges for adult males.
• Confirm the current injection technique and address any adherence concerns.
• Decide whether to continue intramuscular injections, switch to subcutaneous administration, or transition to an alternative formulation.
• Establish the monitoring interval going forward (typically every 3 to 6 months once stable on adult dosing). [1]

The Endocrine Society guideline notes: "Patients transitioning from pediatric to adult care should have testosterone levels confirmed in the adult reference range (400 to 700 ng/dL trough) within the first 3 months after transfer." [1]

Common Failure Modes During Transition

The most documented failure mode is a prescription gap. When a pediatric prescription expires and the adult provider has not yet issued a new one, patients may go 4 to 6 weeks without testosterone. At a half-life of 8 days, serum testosterone drops to near-castrate levels within 3 to 4 weeks of the last injection. [2]

A secondary failure mode is laboratory duplication without interpretation. Adult providers who are unfamiliar with the patient's history may repeat an entire workup before prescribing, adding 6 to 8 weeks of delay. Sending a complete transition summary in advance reduces this risk substantially. [8]

Gender-Affirming Testosterone Therapy: Specific Transition Considerations

Transgender adolescent males on testosterone cypionate for GAHT face an additional layer of complexity. Their care may involve mental health providers, gender specialists, and primary care physicians simultaneously. The Endocrine Society's 2017 clinical practice guideline on transgender health (updated recommendations under review in 2024) recommends that GAHT initiated in adolescence be continued without interruption through the transition to adult care. [10]

Consent and Legal Considerations at Age 18

In the United States, most states require adult informed consent for testosterone therapy. At age 18, the patient becomes the sole legal decision-maker. The transition appointment is a natural moment to re-obtain written informed consent, review the known long-term effects of testosterone therapy, and confirm the patient's current goals. [10]

Fertility Counseling Before Transition

Testosterone suppresses spermatogenesis. For adolescent males on TC who may want biological children, fertility counseling should occur before the transition to adult care, not after. [11] A 2020 review in Fertility and Sterility noted that testosterone-induced azoospermia is reversible in most cases after cessation but that reversal may take 12 to 24 months and is not guaranteed. [11] The receiving adult provider should document whether this counseling occurred.

Bone Density in GAHT Patients

Transgender males who started testosterone before peak bone mass accrual (typically age 25) may have lower bone mineral density than age-matched cisgender males. A baseline DXA scan at transition is warranted if one has not been done within the prior two years. [9] The Endocrine Society recommends repeating DXA every 1 to 2 years until bone density is stable. [10]

Laboratory Monitoring Protocols After Transition

Once the patient is in adult care, monitoring intervals follow adult hypogonadism protocols. These differ from the more frequent surveillance used during adolescent dose escalation.

Standard Adult Monitoring Schedule for Testosterone Cypionate

| Parameter | Frequency (stable dose) | Action threshold | |---|---|---| | Total testosterone (trough) | Every 6 months | <400 ng/dL or >700 ng/dL: adjust dose | | Hematocrit | Every 6 months | >54%: reduce dose or extend interval | | Lipid panel | Annually | LDL >190 mg/dL: lipid management | | Bone density (DXA) | Every 1 to 2 years if risk factors present | T-score <, 2.5: bone protection therapy | | LH / FSH | At transition baseline; annually if etiology unclear | Persistent elevation may indicate primary failure |

[1] [6]

Interpreting Trough Levels After Transition

Trough testosterone (drawn immediately before the next scheduled injection) should fall between 400 and 700 ng/dL for most adult males on intramuscular testosterone cypionate. [1] Values below 300 ng/dL at trough suggest underdosing or a missed injection. Values above 900 ng/dL at trough suggest excessive dosing or an error in injection timing. A 2021 cross-sectional analysis published in the Journal of Clinical Endocrinology and Metabolism found that dose-adjusted trough levels on 100 mg TC every 2 weeks averaged 412 ng/dL (95% CI: 380 to 445 ng/dL), with significant inter-individual variability driven by body composition and injection technique. [12]

When to Refer Back to Endocrinology

Primary care providers managing adult patients formerly under pediatric endocrinology should re-refer to endocrinology if:

• Testosterone levels remain outside range despite two dose adjustments.
• Hematocrit exceeds 54% on the lowest clinically effective dose.
• The patient expresses interest in fertility, requiring gonadotropin therapy rather than testosterone alone.
• Bone density declines more than 5% between two consecutive DXA scans. [1]

Psychosocial and Adherence Considerations in Newly Adult Patients

The transition to adult care coincides with other major life transitions: leaving school, starting college or employment, and losing parental involvement in healthcare. These factors affect adherence more than any pharmacological variable. [13]

Injection Technique and Self-Administration

Many adolescents have injections administered by a parent or clinic nurse. At transition, the adult provider should confirm that the patient can self-administer correctly. Poor injection technique leads to depot failure, variable absorption, and inconsistent trough levels. [6] A brief demonstration at the first adult visit takes five minutes and prevents months of poorly controlled levels.

Mental Health Continuity

Testosterone therapy affects mood, libido, and energy. Any disruption in testosterone levels during transition may destabilize mental health, particularly in patients with a prior history of depression or gender dysphoria. [10] The adult care team should ask about mood at every visit during the first year after transition and coordinate with existing mental health providers.

Insurance and Pharmacy Continuity

Adolescents covered under a parent's insurance plan may lose coverage at age 18 or 26, depending on plan type. The transition planning process should include a review of prescription coverage for testosterone cypionate. Generic TC 200 mg/mL (10 mL vial) is available for approximately $40 to 60 at major pharmacy chains with GoodRx-type discount programs, reducing the financial barrier if insurance coverage lapses. [14]

Testosterone Cypionate Formulation Choices at Transition

Testosterone cypionate is not the only intramuscular testosterone option, but it is the most commonly used in adolescent care in the United States because of its established dosing data and cost profile. [2] At transition, some patients switch formulations.

IM vs. Subcutaneous Administration

Subcutaneous (SQ) testosterone cypionate has gained acceptance as an alternative to intramuscular injection. A 2017 study (N=63) published in Urology found that SQ testosterone cypionate at 75 mg weekly produced mean testosterone levels of 545 ng/dL with lower hematocrit elevation than standard IM dosing. [15] Some patients find SQ injections easier to self-administer. The FDA-approved labeling for testosterone cypionate specifies intramuscular use, but many clinicians use SQ as an off-label approach. [2]

Gel and Patch Alternatives

Testosterone gels (e.g., AndroGel 1.62%) provide daily dosing and more stable serum levels than bi-weekly IM injections. The tradeoff is daily application, potential transfer to partners or children, and higher cost. [6] For adolescents who have been stable on IM TC for years, switching formulations at transition introduces unnecessary variability unless there is a specific indication.

Pellet Therapy

Testosterone pellets (e.g., Testopel) are not recommended at transition without a dedicated specialist, as dose adjustment requires a new insertion procedure. [6]

Summary Table: Adolescent vs. Adult Care Protocols for Testosterone Cypionate

| Domain | Adolescent (12 to 17) | Adult (18+) | |---|---|---| | Starting dose | 50 mg IM every 4 weeks | 100 to 200 mg IM every 1 to 2 weeks | | Dose titration | Every 6 months based on bone age and Tanner staging | Based on trough levels and symptoms | | Bone age X-ray | Every 6 to 12 months | Not needed once growth complete | | DXA | If clinically indicated | Every 1 to 2 years if risk factors | | Monitoring interval | Every 3 to 6 months | Every 6 months (stable) | | Prescriber type | Pediatric endocrinologist | Adult endocrinologist, urologist, or PCP | | Consent | Parental and patient assent | Patient only (adult) |

[1] [6] [10]